Literature DB >> 31949939

Transanal total mesorectal excision for rectal cancer: hype or new hope?

Chien-Chih Chen1,2, Yi-Ling Lai1,2, Andy Yi-Ming Cheng3, Chun-Ho Chu1,2, I-Ping Huang1, Shung-Haur Yang2,4,5.   

Abstract

Rectal cancer has always posed surgical challenges to the colorectal surgeon. The quality of the total mesorectal excision (TME) performed is key in determining local disease control. Unlike the great success in adoption of laparoscopic surgery in colon cancer treatment, studies comparing laparoscopy to open rectal surgery all revealed noninferiority was not achieved. Transanal TME (taTME) is the latest advanced technique pioneered to tackle difficult pelvic dissections. The evolution of taTME surgery in recent years was explored in this review. The outcomes to date on the latest literatures are reviewed, included complications, functional outcomes, oncological results and future clinical researches. taTME, while definitely still in its early stages of development, has steadily accumulated safety and feasibility data. It not only provides a better solution to an old problem that colorectal surgeons have been attempting to tackle for quite some time, but also appears to be quite promising in terms of outcomes on numerous fronts. With structured training models, and proctored clinical application, alongside design and implementation of international-scale large multicenter randomized clinical trials, one can only hope that taTME and its innovations will not only open a new era for colorectal surgery, but also for even more surgical disease pathologies. 2019 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Transanal total mesorectal excision (taTME); laparoscopic rectal surgery; laparoscopic surgery; minimally invasive surgery; rectal cancer; total mesorectal excision (TME)

Year:  2019        PMID: 31949939      PMCID: PMC6955018          DOI: 10.21037/jgo.2019.01.13

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  32 in total

1.  Incidence and Risk Factors for Anastomotic Failure in 1594 Patients Treated by Transanal Total Mesorectal Excision: Results From the International TaTME Registry.

Authors:  Marta Penna; Roel Hompes; Steve Arnold; Greg Wynn; Ralph Austin; Janindra Warusavitarne; Brendan Moran; George B Hanna; Neil J Mortensen; Paris P Tekkis
Journal:  Ann Surg       Date:  2019-04       Impact factor: 12.969

2.  Transanal Total Mesorectal Excision: International Registry Results of the First 720 Cases.

Authors:  Marta Penna; Roel Hompes; Steve Arnold; Greg Wynn; Ralph Austin; Janindra Warusavitarne; Brendan Moran; George B Hanna; Neil J Mortensen; Paris P Tekkis
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

Review 3.  Indications and technique for TEM (transanal endoscopic microsurgery).

Authors:  H Raestrup; K Manncke; B Mentges; G Buess; H D Becker
Journal:  Endosc Surg Allied Technol       Date:  1994-10

4.  Transanal Total Mesorectal Excision Versus Laparoscopic Surgery for Rectal Cancer Receiving Neoadjuvant Chemoradiation: A Matched Case-Control Study.

Authors:  Chien-Chih Chen; Yi-Ling Lai; Jeng-Kae Jiang; Chun-Ho Chu; I-Ping Huang; Wei-Shone Chen; Andy Yi-Ming Cheng; Shung-Haur Yang
Journal:  Ann Surg Oncol       Date:  2015-11-23       Impact factor: 5.344

5.  Transanal minimally invasive surgery (TAMIS) for local excision of benign neoplasms and early-stage rectal cancer: efficacy and outcomes in the first 50 patients.

Authors:  Matthew R Albert; Sam B Atallah; Teresa C deBeche-Adams; Seema Izfar; Sergio W Larach
Journal:  Dis Colon Rectum       Date:  2013-03       Impact factor: 4.585

6.  An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesorectal excision (TaTME).

Authors: 
Journal:  Colorectal Dis       Date:  2018-09       Impact factor: 3.788

7.  Transanal total mesorectal excision (TaTME) for rectal cancer: effects on patient-reported quality of life and functional outcome.

Authors:  T W A Koedam; G H van Ramshorst; C L Deijen; A K E Elfrink; W J H J Meijerink; H J Bonjer; C Sietses; J B Tuynman
Journal:  Tech Coloproctol       Date:  2017-01-02       Impact factor: 3.781

8.  St.Gallen consensus on safe implementation of transanal total mesorectal excision.

Authors:  Michel Adamina; Nicolas C Buchs; Marta Penna; Roel Hompes
Journal:  Surg Endosc       Date:  2017-12-12       Impact factor: 4.584

9.  COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer.

Authors:  Charlotte L Deijen; Simone Velthuis; Alice Tsai; Stella Mavroveli; Elly S M de Lange-de Klerk; Colin Sietses; Jurriaan B Tuynman; Antonio M Lacy; George B Hanna; H Jaap Bonjer
Journal:  Surg Endosc       Date:  2015-11-04       Impact factor: 4.584

10.  Quality of life after rectal cancer surgery: differences between laparoscopic and transanal total mesorectal excision.

Authors:  Marloes Veltcamp Helbach; Thomas W A Koedam; Joep J Knol; Simone Velthuis; H Jaap Bonjer; Jurriaan B Tuynman; Colin Sietses
Journal:  Surg Endosc       Date:  2018-07-02       Impact factor: 4.584

View more
  1 in total

1.  Transanal total mesorectal excision: 3-year oncological outcomes.

Authors:  S Ourô; D Albergaria; M P Ferreira; B Costeira; P Roquete; D Ferreira; R Maio
Journal:  Tech Coloproctol       Date:  2020-10-28       Impact factor: 3.781

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.